Skip to main content
. 2022 Apr 5;86(3):1399–1413. doi: 10.3233/JAD-215511

Fig. 2.

Fig. 2

Study design. The phase I trial enrolled a total of 88 subjects, including the single ascending dose study (part A, 20–90 mg fosgonimeton versus placebo) and the multiple ascending dose study (part B, 20–80 mg fosgonimeton versus placebo) including a fixed-dose study in Alzheimer’s disease (AD) subjects.